Brodalumab Biosimilar Monoclonal Antibody (IL-17RA) for Research

Cat No.: GMP-Bios-ab-082

Pre-Made Brodalumab biosimilar, Whole mAb, Anti-IL17RA/IL17R Antibody: Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Brodalumab (trade name Siliq in the US and Kyntheum in Europe) is a human monoclonal antibody designed for the treatment of inflammatory diseases.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-082-1mg 1mg 243

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Brodalumab biosimilar, Whole mAb, Anti-IL17RA/IL17R Antibody: Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R therapeutic antibody
INN Name Brodalumab
TargetIL17R
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesAmgen;AstraZeneca;Bausch Health Companies;Kyowa Hakko Kirin;LEO Pharma
Conditions ApprovedErythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Psoriasis
Conditions ActiveAxial Spondylarthritis;Systemic scleroderma;Palmoplantar pustulosis
Conditions DiscontinuedAsthma;Crohn's disease;Rheumatoid arthritis
Development TechAbgenix XenoMouse



About target - IL17RA

1. Protein Interleukin-17 receptor A

2. Gene IL17RA

3. Organism Homo sapiens (Human)

Function
Receptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Receptor for IL17A (PubMed:17911633, PubMed:9367539).

Receptor for IL17F (PubMed:19838198, PubMed:17911633).

Binds to IL17A with higher affinity than to IL17F (PubMed:17911633).

Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC (PubMed:16785495).

Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC (PubMed:18684971).

Cytokine binding triggers homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways, ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation (PubMed:16785495, PubMed:24120361, PubMed:17911633, PubMed:18684971, PubMed:21350122).

Involved in antimicrobial host defense primarily promoting neutrophil activation and recruitment at infection sites to destroy extracellular bacteria and fungi (By similarity).

In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells (By similarity).

Plays a role in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection. Stimulates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity).

Involved in antiviral host defense through various mechanisms. Enhances immunity against West Nile virus by promoting T cell cytotoxicity. Contributes to Influenza virus clearance by driving the differentiation of B-1a B cells, providing for production of virus-specific IgM antibodies at first line of host defense (By similarity).

Receptor for IL17C as part of a heterodimeric complex with IL17RE (PubMed:21993848).

(Microbial infection) Receptor for SARS coronavirus-2/SARS-CoV-2 virus protein ORF8, leading to IL17 pathway activation and an increased secretion of pro-inflammatory factors through activating NF-kappa-B signaling pathway.